XML 22 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Feb. 21, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2024    
Current Fiscal Year End Date --12-31    
Entity File Number 001-15911    
Entity Registrant Name IMUNON, INC.    
Entity Central Index Key 0000749647    
Entity Tax Identification Number 52-1256615    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 997 LENOX DRIVE    
Entity Address, Address Line Two SUITE 100    
Entity Address, City or Town LAWRENCEVILLE    
Entity Address, State or Province NJ    
Entity Address, Postal Zip Code 08648    
City Area Code (609)    
Local Phone Number 896-9100    
Title of 12(b) Security Common Stock, Par Value $0.01 Per Share    
Trading Symbol IMNN    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 10.8
Entity Common Stock, Shares Outstanding   14,620,732  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Imunon Inc. as of December 31, 2024 and 2023, and the related consolidated statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of Imunon Inc. as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name WithumSmith+Brown, PC    
Auditor Location East Brunswick, New Jersey    
Auditor Firm ID 100